RU95106629A - Днк, конструкция днк, клетка-хозяин, способ получения рецептора, пептид, антитело, зонд, способ обнаружения - Google Patents

Днк, конструкция днк, клетка-хозяин, способ получения рецептора, пептид, антитело, зонд, способ обнаружения

Info

Publication number
RU95106629A
RU95106629A RU95106629/13A RU95106629A RU95106629A RU 95106629 A RU95106629 A RU 95106629A RU 95106629/13 A RU95106629/13 A RU 95106629/13A RU 95106629 A RU95106629 A RU 95106629A RU 95106629 A RU95106629 A RU 95106629A
Authority
RU
Russia
Prior art keywords
dna
glucagon
receptor
compound
detection
Prior art date
Application number
RU95106629/13A
Other languages
English (en)
Other versions
RU2184779C2 (ru
Inventor
Р.Киндсвогл Вэйн
Us]
Дж.Джелинек Лаура
О.Шеппард Пол
Дж.Грант Фрэнсис
Л.Киджпер Джозеф
С.Фостер Доналд
Лок Си
Дж.О'Хара Патрик
Original Assignee
Зимогенетикс
Зимогенетикс, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/086,631 external-priority patent/US5776725A/en
Application filed by Зимогенетикс, Зимогенетикс, Инк., Инк. (US) filed Critical Зимогенетикс
Publication of RU95106629A publication Critical patent/RU95106629A/ru
Application granted granted Critical
Publication of RU2184779C2 publication Critical patent/RU2184779C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение обеспечивает изолированные молекулы ДНК, содержащие сегмент ДНК, кодирующий рецептор глюкагона. Обеспечены также конструкции ДНК, содержащие первый сегмент ДНК, кодирующий рецептор глюкагона, оперативно соединенный с дополнительными сегментами ДНК, необходимыми для эксперссии первого сегмента ДНК, а также клетки-хозяева, содержащие такие конструкции ДНК. Данное изобретение обеспечивает также способ обнаружения присутствия антагонистов глюкагона, предусматривающий стадии контактирования соединения в присутствии агониста глюкагона с рекомбинантным рецептором глюкагона, сопряженным с ответным путем, при условиях и в течение времени, достаточных для осуществления связывания этого соединения с рецептором и ассоциированного с этим связыванием ответа через путь и обнаружения снижения в стимуляции ответного пути, вызываемого связыванием соединения с рецептором глюкагона по сравнению со стимуляцией ответного пути одним агонистом глюкагона и определение отсюда присутствия антагониста глюкагона.

Claims (1)

  1. Изобретение обеспечивает изолированные молекулы ДНК, содержащие сегмент ДНК, кодирующий рецептор глюкагона. Обеспечены также конструкции ДНК, содержащие первый сегмент ДНК, кодирующий рецептор глюкагона, оперативно соединенный с дополнительными сегментами ДНК, необходимыми для эксперссии первого сегмента ДНК, а также клетки-хозяева, содержащие такие конструкции ДНК. Данное изобретение обеспечивает также способ обнаружения присутствия антагонистов глюкагона, предусматривающий стадии контактирования соединения в присутствии агониста глюкагона с рекомбинантным рецептором глюкагона, сопряженным с ответным путем, при условиях и в течение времени, достаточных для осуществления связывания этого соединения с рецептором и ассоциированного с этим связыванием ответа через путь и обнаружения снижения в стимуляции ответного пути, вызываемого связыванием соединения с рецептором глюкагона по сравнению со стимуляцией ответного пути одним агонистом глюкагона и определение отсюда присутствия антагониста глюкагона.
RU95106629/13A 1992-08-28 1993-08-30 Изолированная молекула днк, кодирующая рецептор глюкагона, днк-конструкция, линия клеток, способ получения рецептора глюкагона, изолированный пептид рецептора глюкагона, изолированное антитело, зонд, способ обнаружения присутствия антагонистов глюкагона RU2184779C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93833192A 1992-08-28 1992-08-28
US07/938,331 1992-08-28
US08/086,631 1993-07-01
US08/086,631 US5776725A (en) 1992-08-28 1993-07-01 Recombinant production of glucagon receptors

Publications (2)

Publication Number Publication Date
RU95106629A true RU95106629A (ru) 1997-03-27
RU2184779C2 RU2184779C2 (ru) 2002-07-10

Family

ID=26774970

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95106629/13A RU2184779C2 (ru) 1992-08-28 1993-08-30 Изолированная молекула днк, кодирующая рецептор глюкагона, днк-конструкция, линия клеток, способ получения рецептора глюкагона, изолированный пептид рецептора глюкагона, изолированное антитело, зонд, способ обнаружения присутствия антагонистов глюкагона

Country Status (12)

Country Link
US (2) US5770445A (ru)
EP (1) EP0658200B1 (ru)
JP (1) JP3515112B2 (ru)
AT (1) ATE285472T1 (ru)
AU (1) AU689078B2 (ru)
CA (1) CA2142819C (ru)
DE (1) DE69333726T8 (ru)
HU (1) HU219674B (ru)
NZ (1) NZ255922A (ru)
PL (1) PL178685B1 (ru)
RU (1) RU2184779C2 (ru)
WO (1) WO1994005789A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162863T3 (es) * 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6340588B1 (en) 1995-04-25 2002-01-22 Discovery Partners International, Inc. Matrices with memories
EP1003904B1 (en) 1997-05-23 2007-07-11 BioArray Solutions Ltd. Color-encoding and in-situ interrogation of matrix-coupled chemical compounds
US6223560B1 (en) * 1998-03-20 2001-05-01 Cerocon S.A. Process of producing a glassy product for multiple applications and products obtained by the process
US6608173B1 (en) * 1998-04-04 2003-08-19 Kenji Sakamoto Method for searching physiologically active substances, process for producing these substances and drugs found by the searching method
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
DK1196566T3 (da) * 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
AU2002239538A1 (en) * 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
EP2096170B1 (en) * 2005-09-19 2011-08-10 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
JP5781308B2 (ja) * 2008-02-19 2015-09-16 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 異種タンパク質を得る方法およびインスリン類似体
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
US9102732B2 (en) * 2009-09-08 2015-08-11 Neopharm Co., Ltd. Antibodies against glucagon receptor and their use
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
KR101840512B1 (ko) 2011-09-20 2018-03-20 아이오니스 파마수티컬즈, 인코포레이티드 Gcgr 발현의 안티센스 조절
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
KR20190044079A (ko) 2016-08-30 2019-04-29 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
SG11201906682YA (en) 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
EP3672620A1 (en) 2017-08-22 2020-07-01 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
DK0567562T3 (da) * 1991-01-17 1996-07-29 Zymogenetics Inc Fremgangsmåde til påvisning af glucagonantagonister
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
ATE285472T1 (de) 2005-01-15
DE69333726T2 (de) 2006-02-23
CA2142819C (en) 2003-08-19
PL307746A1 (en) 1995-06-12
HUT74352A (en) 1996-12-30
JPH08500737A (ja) 1996-01-30
AU689078B2 (en) 1998-03-26
DE69333726D1 (de) 2005-01-27
CA2142819A1 (en) 1994-03-17
PL178685B1 (pl) 2000-06-30
EP0658200A1 (en) 1995-06-21
NZ255922A (en) 1998-01-26
HU9500596D0 (en) 1995-04-28
US5770445A (en) 1998-06-23
JP3515112B2 (ja) 2004-04-05
HU219674B (hu) 2001-06-28
AU5097493A (en) 1994-03-29
DE69333726T8 (de) 2006-04-27
EP0658200B1 (en) 2004-12-22
RU2184779C2 (ru) 2002-07-10
US5919635A (en) 1999-07-06
WO1994005789A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
RU95106629A (ru) Днк, конструкция днк, клетка-хозяин, способ получения рецептора, пептид, антитело, зонд, способ обнаружения
Authier et al. Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B
DK0970213T3 (da) Dödsdomæneholdig receptor
JPS61502399A (ja) 卵胞液から単離したインヒビン
ATE362982T1 (de) ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
CA2413857A1 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
ATE321855T1 (de) Tumor-nekrose-faktor rezeptor 5
BR9806954A (pt) Receptores 6a e 6b do fator de necrose tumoral
US6346388B1 (en) Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
Franck et al. Semisynthesis of an evasin from tick saliva reveals a critical role of tyrosine sulfation for chemokine binding and inhibition
CA2245924A1 (en) A method of identifying agonists and antagonists for tumor necrosis related receptors tr1, tr3 and tr5
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
EP1514932A3 (en) Glucagon receptors
Saito et al. Characterization of the post‐translational modification of recombinant human BMP‐15 mature protein
TW202219062A (zh) 用於特性化ｍｈｃｉ肽結合的測定及試劑
Børglum Jensen et al. Library of sequence-specific radioimmunoassays for human chromogranin A
Rasmussen et al. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view
Rak et al. Spontaneous proteolytic processing of human recombinant anti-mullerian hormone: structural and functional differences of the molecular forms
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
O'Keefe et al. Identification of an Escherichia coli protein impurity in preparations of a recombinant pharmaceutical
WO2006001770A1 (en) Method for identifying modulators of cytokine class i receptor
Nordmann et al. Neurophysin heterogeneity. Difference between newly formed and aged neurosecretory granules.
Michels et al. Structure and functional characterization of the periplasmic N‐terminal polypeptide domain of the sugar‐specific ion channel protein (ScrY porin)
DE60027563D1 (de) Fc-Fusionsproteine des MENSCHLICHEN TUMOR-NEKROSE-FAKTOR-Rezeptors TR10
Nakamura et al. Effects of modification at the fifth residue of μ‐conotoxin GIIIA with bulky tags on the electrically stimulated contraction of the rat diaphragm